Navigation Links
Mylan Successfully Upsizes and Completes Refinancing of Credit Facility
Date:11/14/2011

PITTSBURGH, Nov. 14, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has successfully completed the previously announced refinancing of its existing secured credit facility. The company's new $2.5 billion senior secured credit facility was upsized from the originally planned $2.25 billion and comprises a $1.25 billion revolving credit facility and a $1.25 billion Term Loan A facility. The proceeds were used to repay Mylan's existing secured credit facility and related fees and expenses. Approximately $200 million of the revolving credit facility was drawn at close.

The new senior secured facility matures in 2016 with an initial rate of LIBOR + 200 basis points, which is more than 100 basis points lower than the weighted average rate on the prior facility.

Mylan Chief Financial Officer John Sheehan said: "We are very pleased with the confidence that the financial markets continue to show in Mylan, as it has allowed us to upsize our credit facility while reducing our borrowing costs. With this transaction, we now have refinanced more than $5 billion in new borrowings and credit facilities since 2008, enabling us to significantly extend our debt maturities and enhance our operating flexibility."

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Applauds Obama Administrations Call to Create an "AIDS-Free Generation" Through Global Fight Against HIV/AIDS
2. Mylan to Acquire Pfizer Respiratory Delivery Platform
3. Mylan Receives Approval for Generic Version of MS Contin® Tablets
4. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
5. Mylans Dey Pharma Successfully Obtains Patent Reexamination Certificates for Two Perforomist® Patents
6. Matrix Laboratories Completes Name Change to Mylan Laboratories
7. Mylan Announces Femcon® Fe Settlement Agreement
8. Mylan Announces Intention to Refinance Existing Secured Credit Facility
9. Mylan Comments on Death of Company Co-Founder and Former Chairman and CEO Milan "Mike" Puskar
10. Mylan Applauds Study Highlighting $931 Billion in Savings for U.S. Health Care System Due to Generic Drugs
11. Mylan Announces XELODA® Settlement and License Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 STAAR Surgical Company (NASDAQ: ... lenses and delivery systems for the eye, today announced that ... to the Company,s Board. Mr. Wall ... Boston -based investment firm, for more than nine ... of Directors, and chair of the Corporate Governance Committee and ...
(Date:9/2/2015)... , Sept. 2, 2015   Physicians Rx ... Bernstein has joined the organization as President and ... recently served as President and Chief Executive Officer for ... Chief Executive Officer of Physicians Rx Pharmacy, be responsible ... "We are extremely pleased to bring Gaston on ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has announced ... (Basel, Switzerland - November 26-27, 2015)" conference to their ... overview of the key areas of pharmaceutical regulatory affairs in ... , Macau and Taiwan ... important aspects of gaining and maintaining a successful Marketing Authorisation ...
Breaking Medicine Technology:William P. Wall Appointed to STAAR Surgical Board of Directors 2Gaston L. Bernstein Named President and CEO of Physicians Rx Pharmacy 2Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
... Tim Wentworth, group president for employer and key ... MHS ), is scheduled to present at the Lazard ... 17, 2010 in New York. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO) ... The St. Regis Hotel is scheduled to begin at ...
... Despite national guidelines recommending that inhaled corticosteroid (ICS) ... with mild persistent asthma, a new study finds that ... drugs that combine an ICS and a long-acting beta ... noted based on pharmacy and medical claims. The analysis ...
Cached Medicine Technology:Medco to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 2New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 3New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 4
(Date:9/2/2015)... ... September 02, 2015 , ... ... in the news recently following a decision by the Centers for Medicare & ... likely to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 price ...
(Date:9/2/2015)... ... 02, 2015 , ... Date and time: Oct. 3, 2015, 9 a.m. to ... Tomlinson Road, Bryn Athyn, Pa 19009 , Cost: $50 per person; includes lunch , ... Times best-selling author Sam Keen based on his new book which he co-authored with ...
(Date:9/2/2015)... CA (PRWEB) , ... September 02, 2015 , ... In ... featured by the Huffington Post on August 25th, writer Akela Stanfield detailed her lifelong ... While the author acknowledged that she had always seen herself as someone who would ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... endpoint data collection, cloud analytics and workflow solutions today announced the September ... pharmaceutical researchers to participate in interactive programs in which ERT scientists and ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... healthcare industry announced today the launch of its enhanced, cloud-based mobile ePrescribing application. ... look” and focus on improving prescriber usability. A leader in health technology, RxNT ...
Breaking Medicine News(10 mins):Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2
... New analyses from the Women,s Health Initiative (WHI) confirm that ... healthy postmenopausal women. Researchers report a trend toward an ... of hormone therapy among women who began therapy within 10 ... among women who began hormone therapy more than 10 years ...
... disease activity when added to interferon beta , TUESDAY, ... to standard treatment with interferon beta may reduce multiple ... new study reports. , Previous non-randomized studies found that ... disease activity. , This new phase 2 study ...
... ... 2010 , ... February 16, 2010 -- Aberdeen Group, a Harte-Hanks Company has released a new benchmark ... Telecom Expense Management (TEM) solutions as a strategic foundation and precursor for other ...
... ... all natural food service company manages to grow sales and reduce its ... second year in a row, Service Foods, the largest Home Food service ... after increasing sales. Verus Carbon Neutral once again measured and offset 100% ...
... ... Texas, has contracted with Atlanta-based Premier Anesthesia to manage the anesthesia services for its ... ... hospital in east Texas, has contracted with Atlanta-based Premier Anesthesia to manage the anesthesia ...
... ABBOTT PARK, Ill., Feb. 16 Abbott (NYSE: ... EUR 4.5 billion ( $6.2 billion ) acquisition of ... portfolio of pharmaceutical products and expanding Abbott,s presence in key global ... Abbott expects the acquisition to add approximately $2.9 billion ...
Cached Medicine News:Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 2Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 3Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 4Health News:Added Drug Aids MS Treatment 2Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 2Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 3Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 4Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 5Health News:Service Foods Reduces its Carbon Footprint and Grows Sales 2Health News:Service Foods Reduces its Carbon Footprint and Grows Sales 3Health News:Premier Anesthesia Forges New Partnership with Texas Hospital 2Health News:Abbott Completes Acquisition of Solvay Pharmaceuticals 2Health News:Abbott Completes Acquisition of Solvay Pharmaceuticals 3
Cer-Met series II system....
The Ceracup has a standard profile plastic component with a ceramic insert and the benefit of alumina-alumina contact....
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
Medicine Products: